ZHONGSHENGYAOYE(SZ:002317) Xinda Securities·2026-01-19 08:01Investment Rating - The report assigns a "Buy" rating for the stock of Zhongsheng Pharmaceutical (002317) based on its strong commercial potential and strategic partnerships [1]. Core Insights - The report highlights the successful licensing agreement between Zhongsheng Ruichuang and Qilu Pharmaceutical for the production and commercialization of RAY1225 in China, which is expected to enhance cash flow and maximize future commercialization benefits [2][3]. - RAY1225 is a GLP-1/GIP dual-target peptide drug with promising clinical trial results, showing positive efficacy and safety, with expectations for commercialization by 2027-2028 [2]. - The partnership with Qilu Pharmaceutical, a leading Chinese pharmaceutical company, is seen as a significant advantage for domestic commercialization efforts [3]. Financial Projections - Revenue projections for Zhongsheng Pharmaceutical are estimated at RMB 2.601 billion, RMB 2.978 billion, and RMB 3.449 billion for the years 2025, 2026, and 2027 respectively, with corresponding net profits of RMB 301 million, RMB 395 million, and RMB 508 million [3][4]. - The report anticipates a gradual improvement in earnings per share (EPS), forecasting RMB 0.35, RMB 0.47, and RMB 0.60 for the same years, with price-to-earnings (P/E) ratios decreasing from 61.17 to 36.29 [3][4].